Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Peter S. Goedegebuure"'
Autor:
William G. Hawkins, Richard S. Hotchkiss, Peter S. Goedegebuure, Stacey Plambeck-Suess, Jonathan E. McDunn, Dirk Spitzer
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL, Apo2L) has been shown to exhibit potent and specific apoptotic activity against tumor cells. Several TRAIL constructs have been tried in patients, and the molecule remains under active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025feb5d7259dd3413691bf18f6322c9
https://doi.org/10.1158/1535-7163.c.6532083
https://doi.org/10.1158/1535-7163.c.6532083
Autor:
William G. Hawkins, Richard S. Hotchkiss, Peter S. Goedegebuure, Stacey Plambeck-Suess, Jonathan E. McDunn, Dirk Spitzer
Supplementary Data from A Genetically Encoded Multifunctional TRAIL Trimer Facilitates Cell-Specific Targeting and Tumor Cell Killing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35cb79501581b6c4aa69da40d658ec27
https://doi.org/10.1158/1535-7163.22485792.v1
https://doi.org/10.1158/1535-7163.22485792.v1
Publikováno v:
Cancer Gene Ther
Ovarian cancer is the leading cause of death among women with gynecological cancer, with an overall 5-year survival rate below 50% due to a lack of specific symptoms, late stage at time of diagnosis and a high rate of recurrence after standard therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eb12ed5ec1d2c539fdd5d1f03588ed4
https://europepmc.org/articles/PMC8119242/
https://europepmc.org/articles/PMC8119242/
Autor:
Peter S. Goedegebuure, Jian Ye, Brian A. Belt, Ankit A Patel, David G. DeNardo, Ryan C. Fields, Roheena Z. Panni, William G. Hawkins, Dominic E. Sanford, Ryan C Jacobs, Timothy M. Nywening, David C. Linehan, William E. Gillanders, Booyeon J. Han, Darren R. Cullinan
Publikováno v:
Gut. 67:1112-1123
ObjectiveChemokine pathways are co-opted by pancreatic adenocarcinoma (PDAC) to facilitate myeloid cell recruitment from the bone marrow to establish an immunosuppressive tumour microenvironment (TME). Targeting tumour-associated CXCR2+neutrophils (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb29c99f4f9385cb5bf9530ed23897c1
https://doi.org/10.1136/gutjnl-2017-313738
https://doi.org/10.1136/gutjnl-2017-313738
Autor:
Savas D. Soysal, Xiuli Zhang, Mark A. Sturmoski, Michael D. McLellan, John M. Herndon, Ian S. Hagemann, Nancy B. Myers, Samuel Kim, Shunqiang Li, Tina Primeau, Peter S. Goedegebuure, Lijin Li, Allegra A. Petti, Elaine R. Mardis, Ted H. Hansen, William E. Gillanders, Jasreet Hundal, Christopher A. Miller, Timothy P. Fleming, Tammi L. Vickery, Jeremy Hoog, Matthew J. Ellis
Publikováno v:
Cancer Immunology Research. 5:516-523
Next-generation sequencing technologies have provided insights into the biology and mutational landscape of cancer. Here, we evaluate the relevance of cancer neoantigens in human breast cancers. Using patient-derived xenografts from three patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c200d8ba39a4474c1d9462b84ac6d7fc
https://doi.org/10.1158/2326-6066.cir-16-0264
https://doi.org/10.1158/2326-6066.cir-16-0264
Autor:
Haeseong Park, Leonel Hernandez-Aya, Lindsay L. Peterson, Feng Gao, Ron Bose, William E. Gillanders, Peter S. Goedegebuure, Cynthia X. Ma, Nusayba Bagegni, Foluso O. Ademuyiwa
Publikováno v:
Journal of Clinical Oncology. 37:TPS1114-TPS1114
TPS1114 Background: mTNBC is associated with poor outcomes and lacks targeted therapies. Immune modulation with PD-1/L1 inhibitors are emerging as effective anticancer therapies. In mTNBC, atezolizumab (anti-PD-L1) plus nab-paclitaxel demonstrated an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92078f1d0d02fe7c634b234df6942f5a
https://doi.org/10.1200/jco.2019.37.15_suppl.tps1114
https://doi.org/10.1200/jco.2019.37.15_suppl.tps1114
Publikováno v:
Surgery. 152:S152-S156
One major barrier in the development of pancreas cancer therapeutics is the selective delivery of the drugs to their cellular targets. We have developed previously several sigma-2 ligands and reported the discovery of a component of the receptor for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d6ae80b3d50b71a7feb6a3b917f8629
https://doi.org/10.1016/j.surg.2012.05.014
https://doi.org/10.1016/j.surg.2012.05.014
Autor:
Albert C. Lockhart, Steven Sorscher, Andrea Wang-Gillam, Benjamin R. Tan, Rama Suresh, Jonathan B. Mitchem, Peter S. Goedegebuure, Joel Picus, Stacey Plambeck-Suess, John R. Hornick, Peter O. Simon, W. Hawkins
Publikováno v:
Investigational New Drugs. 31:707-713
Purpose This phase I study was conducted to determine the safety profile and maximum tolerated dose (MTD) of IMP321, a soluble lymphocyte activation gene-3 (LAG-3) Ig fusion protein and MHC Class II agonist, combined with gemcitabine in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e2460a4af70b0176f8849aeecd0ded
https://doi.org/10.1007/s10637-012-9866-y
https://doi.org/10.1007/s10637-012-9866-y
Autor:
Sojung Kim, Kenneth M. Murphy, Peter S. Goedegebuure, John M. Herndon, Ansuman T. Satpathy, Brian A. Belt, Lijin Li, Timothy P. Fleming, William E. Gillanders, Ted H. Hansen
Publikováno v:
Proceedings of the National Academy of Sciences. 109:12716-12721
Activation of naïve cluster of differentiation (CD)8 + cytotoxic T lymphocytes (CTLs) is a tightly regulated process, and specific dendritic cell (DC) subsets are typically required to activate naive CTLs. Potential pathways for antigen presentation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::498a77a74dc7c482f6a6b1d95a455c10
https://doi.org/10.1073/pnas.1203468109
https://doi.org/10.1073/pnas.1203468109
Autor:
Peter S. Goedegebuure, T. Mohanakumar, Cynthia X. Ma, Feng Gao, Venkataswarup Tiriveedhi, Craig Lockhart, Michael Naughton, Timothy P. Fleming, William E. Gillanders
Publikováno v:
Breast Cancer Research and Treatment. 138:109-118
Mammaglobin-A (Mam-A) is a 10 kDa secretory protein that is overexpressed in 80 % of primary and metastatic human breast cancers. Previous studies from our laboratory demonstrated that Mam-A cDNA vaccine can induce Mam-A-specific CD8 T cell responses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::758acdd13b942d2211beeddf3decfd40
https://doi.org/10.1007/s10549-012-2110-9
https://doi.org/10.1007/s10549-012-2110-9